Oral Antibiotics in Clinical Development for Community-Acquired Urinary Tract Infections-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Oral Antibiotics in Clinical Development for Community-Acquired Urinary Tract Infections

Published:2021-08-06 Issue:4 Volume:10 Page:1815-1835
ISSN:2193-8229
Container-title:Infectious Diseases and Therapy
language:en
Short-container-title:Infect Dis Ther

Author:

Veeraraghavan Balaji,Bakthavatchalam Yamuna Devi,Sahni Rani Diana

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Microbiology (medical)

Link

https://link.springer.com/content/pdf/10.1007/s40121-021-00509-4.pdf

Reference78 articles.

1. Robilotti E, Deresinski S. Carbapenemase-producing Klebsiella pneumoniae. F1000Prime Rep. 2014;6:80.

2. D’Angelo RG, Johnson JK, Bork JT, et al. Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria. Expert Opin Pharmacother. 2016;17(7):953–67.

3. van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence. 2017;8(4):460–9.

4. Sanchez GV, Master RN, Karlowsky JA, et al. In vitro antimicrobial resistance of urinary Escherichia coli isolates among US outpatients from 2000 to 2010. Antimicrob Agents Chemother. 2012;56(4):2181–3.

5. Kaye KS, Gupta V, Mulgirigama A, et al. Antimicrobial resistance trends in urine Escherichia coli isolates from adult and adolescent females in the United States from 2011 to 2019: rising ESBL strains and impact on patient management. Clin Infect Dis. 2021;ciab560.

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current state and novel outlook on prevention and treatment of rising antibiotic resistance in urinary tract infections;Pharmacology & Therapeutics;2024-09

2. In vitro effects of the new oral β-lactamase inhibitor xeruborbactam in combination with oral β-lactams against clinical Mycobacterium abscessus isolates;Microbiology Spectrum;2024-07-02

3. Therapies in preclinical and in early clinical development for the treatment of urinary tract infections: from pathogens to therapies;Expert Opinion on Investigational Drugs;2024-05-09

4. Impact of acquired broad-spectrum β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) alone or in combination with avibactam and taniborbactam β-lactamase inhibitors in Escherichia coli;Antimicrobial Agents and Chemotherapy;2023-10-18

5. Synthetic and Mechanistic Investigations in cis-3-(Substituted acetoxy) azetidin-2-ones from cis-3-Hydroxyazetidin-2-ones: Potential Synthons for Pharmacophoric Hybridized Molecules;Letters in Organic Chemistry;2023-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3